Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient

Despite decades of research and clinical trials, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and typically fatal. Current treatments may provide modest increases in progression-free survival but can come with significant adverse effects and are disaggregated from the di...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, David, Zambelli, Jessica, Lara, Montana Kay, Wolf, Trevor Hamilton, McDonald, Amber, Lee, Erica, Abou-Elkacem, Lotfi, Gordon, Eva J., Baum, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175697/
https://www.ncbi.nlm.nih.gov/pubmed/37188199
http://dx.doi.org/10.3389/fonc.2023.1192792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175697/
https://www.ncbi.nlm.nih.gov/pubmed/37188199
http://dx.doi.org/10.3389/fonc.2023.1192792

Ejemplares similares